FIGURE 2:

The higher potency of the erlotinib + calcitriol combination compared with erlotinib alone to suppress PTG enlargement in rat SHPT associates with marked reductions in parathyroid ADAM17. (A) Scheme of the experimental protocol. (B) Top: representative immunostaining for parathyroid ADAM17 expression. Magnification ×200; bottom: bars and error bars represent the mean ± SEM of PTG weight/body weight from 5/6NX rats fed a high P diet (HP) and receiving vehicle (HP), or calcitriol (HP + 1,25D); erlotinib (HP + ertotinib), or the combination (HP + erlotinib + 1,25D), at the concentrations specified in the ‘Methods’ section. * and ** indicate P < 0.05 and P < 0.01 versus HP.